- Home
- RNXT vs GRCE Comparison
RNXT vs GRCE Comparison
Compare RNXT & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- GRCE
- Stock Information
- Founded
- RNXT 2012
- GRCE 2002
- Country
- RNXT United States
- GRCE United States
- Employees
- RNXT N/A
- GRCE N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- GRCE
- Sector
- RNXT Health Care
- GRCE
- Exchange
- RNXT Nasdaq
- GRCE NYSE
- Market Cap
- RNXT 44.6M
- GRCE 42.1M
- IPO Year
- RNXT 2021
- GRCE N/A
- Fundamental
- Price
- RNXT $1.30
- GRCE $2.94
- Analyst Decision
- RNXT Strong Buy
- GRCE Strong Buy
- Analyst Count
- RNXT 2
- GRCE 1
- Target Price
- RNXT $7.25
- GRCE $12.00
- AVG Volume (30 Days)
- RNXT 169.3K
- GRCE 53.8K
- Earning Date
- RNXT 08-12-2025
- GRCE 06-23-2025
- Dividend Yield
- RNXT N/A
- GRCE N/A
- EPS Growth
- RNXT N/A
- GRCE N/A
- EPS
- RNXT N/A
- GRCE N/A
- Revenue
- RNXT $240,000.00
- GRCE N/A
- Revenue This Year
- RNXT $3,186.05
- GRCE N/A
- Revenue Next Year
- RNXT $291.93
- GRCE N/A
- P/E Ratio
- RNXT N/A
- GRCE N/A
- Revenue Growth
- RNXT N/A
- GRCE N/A
- 52 Week Low
- RNXT $0.75
- GRCE $1.75
- 52 Week High
- RNXT $1.69
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- RNXT 55.53
- GRCE N/A
- Support Level
- RNXT $1.31
- GRCE N/A
- Resistance Level
- RNXT $1.42
- GRCE N/A
- Average True Range (ATR)
- RNXT 0.06
- GRCE 0.00
- MACD
- RNXT -0.01
- GRCE 0.00
- Stochastic Oscillator
- RNXT 56.25
- GRCE 0.00
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.